Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Mesto imunoterapije pri zdravljenju raka
Authors:ID Grašič-Kuhar, Cvetka (Author)
Files:.pdf PDF - Presentation file, download (817,26 KB)
MD5: 9A6FF60E671AB2D0B5D07664820A505D
PID: 20.500.12556/dirros/70dc60aa-3a53-4f0a-b748-e6b675a52142
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Začetni poskusi zdravljena z imunoterapijo segajo v leto 1893.Skoraj stoletje kasneje pa so bila odobrena prva zdravila, ki jih štejemo med imunoterapijo, kot sta interferon in interlevkin. Vlogo imunskega sistema pri raku znanstveniki v zadnjih letih razlagajo s pomočjo protitumorskega imunskega cikla. V prvem koraku tega cikla pride do sproščanja tumorskih antigenov (neoantigenov), ki jih antigen predstavitvene celice spoznajo in ujamejo. V drugem koraku jih v bezgavkah predstavijo celicam T. Za aktivacijo in determinacijo celic T v smeri citotoksičnih T-celic je potreben še dodaten stimulatorni signal. Morebitni inhibitorni signali pa aktivacijo celic T zavirajo oz. preprečujejo čezmerno aktivacijo in avtoimunost. Aktivirane celice T po krvi potujejo v tumor. Tumorsko celico prepoznajo prek T-celičnega receptorja. S tem preide do uničenja tumorske celice. V sami tumorski stromi pa so lahko različni inhibitorni signali, ki delovanje citotoksičnih celic T onemogočijo. V prispevku so predstavljeni možni načini vplivanja na protitumorski imunski cikel in trenutno registrirana zdravila s področja imunoterapije.
Keywords:imunoterapija, protitumorski imunski cikel, stimulatorni signali
Publication status:Published
Publication version:Version of Record
Year of publishing:2017
Number of pages:str. 6-11
Numbering:Letn. 21, št. 2
PID:20.500.12556/DiRROS-8193 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:2843771 New window
Copyright:by Authors
Publication date in DiRROS:16.03.2018
Views:3617
Downloads:1004
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:16.03.2018

Secondary language

Language:English
Title:Role of immunotherapy in cancer treatment
Abstract:The immunotherapy era began in 1893. Nearly a hundred years later, the first immunotherapy drugs were approved, for instance interferon and interleukin. The role of the immune system in cancer is best represented by the cancer-immunity cycle. In the first step of the cycle, tumor neo-antigens are released and, subsequently, captured by the antigen-presenting cells. In the second step, neo-antigens are presented to the T-cells in the lymph nodes. But additional co-stimulatory signals are needed for the priming and the activation of T cells. At that level, the potential inhibitory signals inhibit or prevent the hyperactivation of T cells and autoimmunity. The activated T cells migrate through circulation into the tumor tissue. A tumor cell is detected by a T-cell receptor. The result of this process is the so-called T-cell killing. A tumor stroma, however, can present different inhibitory signals that inhibit the function of cytotoxic T cells. The article presents the different ways of influencing the cancer-immunity cycle and the readily-approved immunotherapy drugs.


Archive

niGradiv

Back